Phase 2 N=5 Salvage Ovarian FANG™ Vaccine + Bevacizumab
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 2 N=584 Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
Depression, Bipolar
Primary: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale Total Score at Week 6 — -11.1; -13.0; -15.1; -13.7 units on a scale — p=0.1292
Phase 2 N=298 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 — -0.24; -0.16; -0.35; -0.66 percent of HbA1c — p=.755
Phase 2 N=819 Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 8 — -12.5; -13.4; -14.6 Units on a scale — p=0.2404
Phase 2 N=41 Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Antiphospholipid Syndrome
Primary: Effects of Fluvastatin on Proinflammatory and Prothrombotic Biomarkers (BMR) in aPL Positive Patients — 31.2; 12.2; 0.4; 2.7 pg/mL
Phase 2 N=95 Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Melanoma (Skin)
Primary: Progression-free Survival at 6 Months — 32.8; 56.1 % of patients alive and progression free
Phase 2 N=107 Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Adenomatous Polyp
Primary: Adenoma Recurrence Rate for the Treatment Arm Relative to Placebo — 0.595; 0.581 proportion of participants — p=0.448
Phase 2 N=131 Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
Metastatic Breast Cancer
Primary: Progression-free Survival — 10.3; 5.1 months — p=0.02
Phase 2 N=38 N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder
Bipolar Disorder
Primary: Number of Patients Demonstrating a > 50% Decrease in Depression Scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) — 3; 2; 5; 6 Participants
Phase 2 N=12 Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Number of Subjects Who Died — 0; 0; 0; 0 Participants
Phase 2 N=571 Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
Type 2 Diabetes Mellitus
Primary: Change in HbA1c (%) at 16 Weeks — -0.33; -0.40; -0.49; -0.62 % glycated haemoglobin — p=0.1449
Phase 2 N=38 Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder
Bipolar Disorder
Primary: NEW Tx Scale — 23.54; 37.75 units on a scale
Phase 2 N=469 A Study for Participants With Major Depression
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in the 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score — -13.2; -12.6; -14.7 units on a scale — p=0.494
Phase 2 N=52 A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
Castration-Resistant Prostate Cancer (CRPC)
Primary: Number of Participants With Adverse Events (AEs) — 43; 27; 5; 17 Participants